Cipla

Global Pharmaceutical Quality Summit Amplifies Conversations on Making Quality Pharmaceuticals in India, Sustainably, for the World

Day 2 of IPA's Pharmaceutical Quality Summit brought together global leaders and regulators across industries, emphasizing the importance of a…

3 years ago

New segment is opening- Phytopharmaceuticals

New Delhi, July 24, 2021: In the complex environment where pharmaceuticals, nutraceuticals, AYUSH medicines, cosmeceuticals and herbal products and extracts, here…

3 years ago

Cipla gets USFDA nod for inhalation product

Drug major Cipla NSE 0.65 % on Wednesday said it has received final approval from the US health regulator for Arformoterol Tartrate…

3 years ago

Bidencare boost for desi pharma companies

Mumbai, November 11, 2020: The Indian pharma sector is expected to benefit from the Biden presidency on the back of…

4 years ago

Stempeutics out licenses its novel stem cell product “Stempeucel-DFU” to Cipla for treating non healing Diabetic Foot Ulcer (DFU)

Diabetic foot is one of the most significant and devastating complications of diabetes Out of approx. 70 million diabetics in India,…

5 years ago

Sudarshan Pharma Industries Ltd.: The Pharma Giant in the Making Announces IPO and Expansion in the MENA Region

Mumbai, June 01, 2019: In a cloud of an organised healthcare ecosystem, the demand for speciality chemicals and pharmaceutical products…

5 years ago

Cipla and Wellthy Therapeutics Announce Partnership to offer Digital Therapeutics for Diabetes and Cardiovascular Diseases

New Delhi, February 20, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and Wellthy…

6 years ago

Acquisition of Avenue Therapeutics to be Credit Neutral for Cipla

New Delhi, December 18, 2018: India Ratings and Research (Ind-Ra) believes that Cipla Limited’s (IND AAA/Stable) proposed acquisition of the…

6 years ago

InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the US

Upon first stage closing, InvaGen Pharmaceuticals Inc., a Cipla subsidiary (“InvaGen”), to acquire shares representing a 33.3% stake in Avenue…

6 years ago

Cipla announces Q2 FY19 results

Mumbai, November 28, 2018: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for quarter ended September…

6 years ago